About Chance

Chance Pharmaceuticals is a clinical-stage biotechnology company focusing on discovering, developing
and commercializing transformative inhalation therapies for the world’s most debilitating diseases

Founded in 2015 by a team of passionate and experienced experts in inhalation therapy, our vision is to
harness the potential of inhalation therapy to improve and transform the lives of
people living with the diseases for which more treatment options are needed.



Closed a license-in Aerami Therapeutics for PAH treatment

Completed C & C+ round financing of about $30Million  in Q4

Complete ANDA submission for CXF11


Completed B round financing of about $12M in January

Listed as Quasi Unicorn company in Hangzhou in 2019 and 2020

Completed pivotal BE study for CXF11


Completed a pilot BE study for CXF 11 in November


Selected as one of the 60 “Kunpeng”companies by The Future Science and Technology City of Hangzhou


Closed A round financing of $8M in December


Secured seed financing in April


Founded in Oct 2015 in Hangzhou as a start-up biotech company focusing on inhalation therapies


Dr. Donghao Chen
Dr. Lan Chen
Co-founder and SVP
Guobao Zhao
Peng (James) Huang
Co-founder and VP


Selected as a quasi-unicorn enterprise in Hangzhou in 2021

Successfully identified as the R&D center of science and technology enterprises in Yuhang District, Hangzhou in 2019

Successfully recognized as a high-tech enterprise in Hangzhou in 2018

Won the "China's Top 80 Healthcare Innovation Enterprises" in 2020

Recognized as a small and medium-sized science and technology enterprise

Selected as a quasi-unicorn enterprise in Hangzhou in 2020

Won the third place in the Zhejiang Province Division of the National Innovation and Entrepreneurship Competition and the National Outstanding Award in 2019

Won the title of Hangzhou "Young Eagle Plan" Enterprise in 2016

Listed as the first top 60 recipients for "Kunpeng Plan"  in future technology city in Hangzhou in 2018